Pfizer Cuts Deal to Escape Trump Pharma Tariffs: The Brief

PFIZER STRUCK a deal with the Trump administration that would give it a three-year reprieve from the president’s promised pharmaceutical tariffs in exchange for selling some drugs at a discount on a direct-to-consumer website called TrumpRx, Damian Garde, Rachel Cohrs Zhang, and Hadriana Lowenkron report.

• The deal appears to resolve two major threats facing Pfizer: staving off more damaging drug pricing policies and shielding the company from future tariffs imposed by the administration’s Section 232 investigation into whether the cost of medicine represents a national security threat.
• It’s the latest example of the transactional nature of winning ...